Related Experiment Video

Updated: May 22, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Patent Landscape and Technological Trajectory of Drug Delivery Systems for Overcoming Drug Resistance in Non-small

Feiyan Wu1, Xinglinzi Tang1, Xinyi Luo1

  • 1Central Lab, Shenzhen Bao'an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China.

Recent Patents on Anti-Cancer Drug Discovery
|May 21, 2026
PubMed

Insights

Drug resistance in non-small cell lung cancer (NSCLC) necessitates new delivery systems. Patent analysis reveals a surge in nano and coupled delivery innovations, with emerging technologies like exosomes and siRNA showing promise for improved treatment strategies.

Area of Science:

  • Biomedical Engineering
  • Drug Delivery Systems
  • Oncology

Background:

  • Drug resistance in non-small cell lung cancer (NSCLC) significantly limits treatment effectiveness.
  • A need exists for systematic analysis of anti-drug resistance delivery systems in NSCLC.
  • Innovation in drug delivery is crucial for overcoming therapeutic challenges in NSCLC.

Purpose of the Study:

  • To systematically analyze patent application trends and delivery system types for overcoming drug resistance in NSCLC over the past two decades.
  • To evaluate the evolution, value, and effectiveness of anti-drug resistance delivery technologies in NSCLC.
  • To provide guidance for optimizing research and development (R&D) strategies and patent portfolios.

Main Methods:

  • Comprehensive analysis of patent data from WIPO, Espacenet, and Incopat global patent databases.
  • Focus on patent application trends, delivery system classifications, and technological evolution.
  • Assessment of patent value and effectiveness, particularly concerning drug resistance mechanisms.

Main Results:

  • Continuous growth in patent applications indicates progressive innovation in anti-drug resistance delivery for NSCLC.
  • Nano delivery (56.6%) and coupled delivery (28.3%) are dominant technologies, with emerging systems like exosomes, vesicles, and siRNA gaining traction.
  • Technological evolution shows a shift from single-carrier systems to intelligent, responsive delivery, with recent focus on stimuli-responsive nanosystems and combination therapy.

Conclusions:

  • High-value patents integrate multiple technologies to overcome drug resistance, enhance precise delivery, and minimize toxicity in NSCLC.
  • The study provides a theoretical basis and practical guidance for R&D strategy and patent portfolio optimization in this field.
  • Continued innovation in advanced drug delivery systems is essential for improving NSCLC treatment outcomes.
Keywords:
Non-small cell lung cancerdrug delivery systemdrug resistanceevolution processnano delivery systempatent analysisstimuli-responsive delivery systemstechnical efficacy

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...